Aetna Cancer Pathways Program Aims For 'Value-Based' Prescribing
This article was originally published in The Pink Sheet Daily
Executive Summary
“For many malignancies, there is no ‘best treatment’ but there may be tremendous differences in cost,” Aetna National Medical Director, Oncology Solutions Michael Kolodziej says.
You may also be interested in...
UnitedHealth Cancer Care Pilot Reduced Overall Costs Despite Higher Drug Spending
The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.